Zhang, Jian
Hu, Xihao
Wang, Jin
Sahu, Avinash Das
Cohen, David
Song, Li
Ouyang, Zhangyi
Fan, Jingyu
Wang, Binbin
Fu, Jingxin
Gu, Shengqing
Sade-Feldman, Moshe
Hacohen, Nir
Li, Wuju
Ying, Xiaomin
Li, Bo
Liu, X. Shirley
Funding for this research was provided by:
NCI grants U01 (CA226196)
NCI grants U24 (CA224316)
National Key R&D Program of China grant (2017YFC0908300)
CPRIT (RR170079)
Article History
Received: 28 January 2019
Accepted: 31 October 2019
First Online: 26 November 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: XSL is a cofounder and board member of GV20 Oncotherapy and Scientific Advisory Board (SAB) member of 3DMed Care. NH is a founder and SAB member of Neon Therapeutics. XH conducted the work in this study as a postdoctoral fellowship at Dana-Farber Cancer Institute, and he is now an employee of GV20 Therapeutics. The remaining authors declare that they have no competing interests.